|Calculated MW||137910 Da|
|Other Names||Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340, ERBB2, HER2, MLN19, NEU, NGL|
|Target/Specificity||A synthetic peptide corresponding to residues surrounding tyrosine 1139 of human HER2 / ErbB2 was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||HER2 (ErbB2) Antibody Phospho (pY1139) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||HER2, MLN19, NEU, NGL|
|Function||Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.|
|Cellular Location||Isoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm, perinuclear region. Nucleus Note=Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1 Isoform 3: Cytoplasm. Nucleus.|
|Tissue Location||Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
HER2 (ErbB2, epidermal growth factor receptor 2) is one of the four members of the ErbB receptor family of transmembrane receptor-like tyrosine kinases (1). The kinase activity of HER2 can be activated without ligand if it is overexpressed, and by association with other HER proteins (2). Overexpression of HER2 is detected in almost 40% of human breast cancers (3). Therefore, HER2 is considered one of the major targets for the treatment of breast cancer and other carcinomas. Binding of c-Cbl ubiquitin ligase to Tyr1112 of HER2 leads to poly-ubiquitination of HER2 and enhances its degradation (4). Similar to other growth factors, HER2 exhibits intrinsic protein tyrosine kinase activity and undergoes autophosphorylation (Y1023, Y1248, Y1139, and Y1222). A phosphorylation at tyrosine 1139 has been identified to induce the binding of Src to HER2, leading to HER2 activation of Stat3 alpha (5).
1. Muthuswamy SK et al. Mol Cell Biol 19:6845-6857 (1999)
2. Qian X et al. Proc Natl Acad Sci USA 91:1500
3. Dittadi R, M Gion J Natl Cancer Inst 92:1443-1444 (2000).
4. Klappe LN et al. Cancer Res 60:3384-3388 (2000).
5. Ren Z, Schaefer TS J Biol Chem 277(41):38486-93 (2002).
If you have any additional inquiries please email technical services at email@example.com.